Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future

Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: Past, present, and future

Glucagon-like peptide-1 (GLP-1)–based therapy improves glycaemic control through multiple mechanisms, with a low risk of hypoglycaemia and the additional benefit of clinically relevant weight loss. Since Starling and Bayliss first proposed the existence of intestinal secretions that stimulate the pa...

Full description

Bibliographic Details
Main Authors: Sanjay Kalra, Manash P Baruah, Rakesh K Sahay, Ambika Gopalakrishnan Unnikrishnan, Shweta Uppal, Omolara Adetunji
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2016-01-01
Series:Indian Journal of Endocrinology and Metabolism
Subjects:
Beyond glycaemic control
comparison of glucagon-like peptide-1 receptor agonists
efficacy
glucagon-like peptide-1 receptor agonists
type 2 diabetes mellitus
Online Access:http://www.ijem.in/article.asp?issn=2230-8210;year=2016;volume=20;issue=2;spage=254;epage=267;aulast=Kalra

Internet

http://www.ijem.in/article.asp?issn=2230-8210;year=2016;volume=20;issue=2;spage=254;epage=267;aulast=Kalra

Similar Items